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SESSION I
CARDIOVASCULAR DISEASE
CV1
HEALTH PREFERENCES AFTER CABG OR PCI FOLLOWING
AN ACUTE MYOCARDIAL INFARCTION
Radeva J, Reed S,Weinfurt K,Anstrom K,Velazquez E, Schulman KA
Duke Clinical Research Institute, Durham, NC, USA
OBJECTIVES: To conduct a longitudinal comparison of
reported health preferences for patients who underwent coro-
nary artery bypass grafting (CABG) or percutaneous coronary
intervention (PCI) after having an acute myocardial infarction
(MI). METHODS: Patient preferences were measured using
community-based utility weights derived from the EuroQol-5D
questionnaire. The analysis included 1093 patients in the multi-
national VALsartan In Acute myocardial iNfarcTion (VALIANT)
Trial who underwent CABG (n = 137) or PCI (n = 956) within
3 weeks of a qualifying MI. We employed a linear mixed-effects
regression model to compare health preferences between groups
at speciﬁc times while controlling for baseline patient character-
istics including demographics, comorbidities, treatment-related
factors (e.g. thrombolytics), and prognostic factors (e.g. Killip
class, heart failure severity). Patients who died were assigned
scores of 0 for all subsequent time points. We tested for differ-
ences in mortality using a Cox proportional hazards regression
model. RESULTS: Patients who underwent CABG post-MI ini-
tially reported signiﬁcantly lower preference scores than those
who underwent PCI (p < 0.0001 at 2 weeks, 95% conﬁdence
interval [CI] for difference: 0.1046 to 0.2061). There were no
signiﬁcant differences in preference scores at 3 months (p =
0.5891) or 6 months (p = 0.1375). However, by 1 year, patients
with CABG reported signiﬁcantly higher preference scores than
those with PCI, and this difference was maintained at 2 years (p
= 0.0150 at 1 year, 95% CI for difference: -0.1355 to -0.01461;
p = 0.0212 at 2 years, 95% CI for difference: -0.1717 to 
-0.01387). The results were consistent across various model
speciﬁcations. Within the ﬁrst 2 years, 5.1% of CABG-treated
patients underwent a subsequent revascularization procedure
compared to 18.6% of PCI-treated patients (p < 0.0001). Within-
trial mortality was comparable between the groups (CABG:
7.3%, PCI: 7.4%; p = 0.7435). CONCLUSIONS: Post-MI
patients who had CABG versus PCI initially reported lower
health preferences. But by 1 year, reported health preferences
were greater for CABG-treated patients relative to PCI-treated
patients.
CV2
CARDIOVASCULAR RISK OF SELECTIVE CYCLOOXYGENASE-
2 INHIBITORS COMPARED TO OTHER NONSTEROIDAL 
ANTI-INFLAMMATORY AGENTS: AN OBSERVATIONAL STUDY
OF A MEDICAID POPULATION
Shaya FT, Blume SW, Blanchette CM, Mullins CD,Weir MR
University of Maryland, Baltimore, MD, USA
OBJECTIVE: To examine the cardiovascular risk of selective
cyclooxygenase-2 (COX-2) inhibitors compared to non-speciﬁc
conventional nonsteroidal anti-inﬂammatory agents (NSAIDs) in
a high-risk Medicaid population. METHODS: All medical and
prescription claims for non-institutionalized Maryland Medicaid
enrollees who received at least one prescription for a COX-2 or
NSAID between January 2000 and June 2002 were retrieved.
Selected for study were adults with no use in the ﬁrst six months,
and who claimed at least 60 total days of supply over the study
period. Patients who took both a COX-2 and an NSAID were
classiﬁed as COX-2 users. Those having any use of the NSAID
naproxen were excluded, as studies have already indicated
naproxen has some cardiovascular protective effect compared to
other NSAIDs. The primary outcome variable was the combined
incidence of cardiovascular, hemorrhagic, and unknown deaths,
nonfatal myocardial infarctions, nonfatal strokes, and pul-
monary and venous embolism/thrombosis. To adjust for con-
founding by indication, we developed a logistic model of
propensity for COX-2 treatment and stratiﬁed patients by quin-
tiles of their propensity score. Model variables included age, sex,
race, COX-2 indications (history of gastrointestinal problems,
osteoarthritis, rheumatoid arthritis, back pain, acute pain), 
and cardiovascular risk factors (hypertension, hyperlipidemia,
obesity, diabetes, renal problems, alcohol/tobacco/drug abuse,
and prior cardiovascular events). RESULTS: Sample COX-2
users numbered 1208 and non-naproxen NSAID users numbered
5274. Overall incidence of the primary outcome was 14%.
Seventy percent were female, 40% were African-American, and
30% were over 50 years old. The Mantel-Haenszel average of
the propensity-adjusted odds-ratios showed no signiﬁcant effect
of COX-2 use on cardiovascular risk (OR, 1.11; 95% CI,
0.93–1.32; p = 0.259). CONCLUSIONS: We did not ﬁnd that
COX-2 inhibitors increased cardiovascular risk over non-
naproxen NSAIDs in a high-risk Medicaid population. Study
limitations include its restriction to the Medicaid population and
the 2-year maximum observation period.
CV3
THE USE OF A PROBABILISTIC DECISION MODEL TO ASSESS
THE COST-EFFECTIVENESS OF DRUG-ELUTING STENTS IN
ALTERNATIVE PATIENT SUB-GROUPS
Sculpher M, Hawkins NS1
1University of York,York, United Kingdom
OBJECTIVES: To use existing evidence on the drug-eluting stent
(DES) CYPHER to assess its cost-effectiveness from a UK health
service perspective. To analyse the degree of variation in cost-
effectiveness by patient sub-group as represented by evidence
from the alternative trials. METHODS: A probabilistic decision
model was developed within which to synthesise available clini-
cal, cost and utility evidence. The model compared the use of
CYPHER and bare metal stents in the alternative patient sub-
groups. Clinical data on rates of further revascularisation and
non-fatal myocardial infarction were taken from three published
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